Stay updated on Entrectinib vs Crizotinib in ROS1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Entrectinib vs Crizotinib in ROS1 NSCLC Clinical Trial page.

Latest updates to the Entrectinib vs Crizotinib in ROS1 NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe version history now includes a new entry 'Revision: v3.3.3'. Entries for 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a new version on 2025-12-04 updating the Study Status and Contacts/Locations; the 2025-11-04 entry was removed.SummaryDifference0.3%

- Check36 days agoChange DetectedA new revision entry v3.3.2 was added to the history and the previous revision v3.2.0 was removed.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page removed the government funding status notice. This change does not affect the study data, status, or records displayed on the page.SummaryDifference0.4%

- Check51 days agoChange DetectedA new Study Status entry (version 61) was added on 2025-11-04 reflecting status updates from 2025-11-02, and an earlier entry from 2025-10-06 was removed.SummaryDifference0.2%

- Check58 days agoChange DetectedThe new screenshot shows updated entries in the Record History, with multiple updates to Study Status and Contacts/Locations for NCT04603807. These updates indicate ongoing maintenance of recruitment status and trial details.SummaryDifference0.1%

Stay in the know with updates to Entrectinib vs Crizotinib in ROS1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Entrectinib vs Crizotinib in ROS1 NSCLC Clinical Trial page.